DUOPA Drug Patent Profile

« Back to Dashboard

Which patents cover Duopa, and when can generic versions of Duopa launch?

Duopa is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in DUOPA is carbidopa; levodopa. There is one drug master file entry for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the carbidopa; levodopa profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Duopa

A generic version of DUOPA was approved as carbidopa; levodopa by DR REDDYS LABS SA on August 28^th, 1992.

Summary for DUOPA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	7
Patent Applications:	58
Drug Prices:	Drug price information for DUOPA
What excipients (inactive ingredients) are in DUOPA?	DUOPA excipients list
DailyMed Link:	DUOPA at DailyMed

See drug prices for DUOPA

Pharmacology for DUOPA

Drug Class

Aromatic Amino Acid

US Patents and Regulatory Information for DUOPA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	DUOPA	carbidopa; levodopa	SUSPENSION;ENTERAL	203952-001	Jan 9, 2015		RX	Yes	Yes

EU/EMA Drug Approvals for DUOPA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Amneal Pharma Europe Ltd	Numient	levodopa, carbidopa	EMEA/H/C/002611Symptomatic treatment of adult patients with Parkinson’s disease	Withdrawn	no	no	no	2015-11-19

DUOPA Market Dynamics, Financial Trajectory, Competition, and Patent Outlook

Last updated: November 5, 2026

DUOPA is AbbVie’s carbidopa/levodopa enteral suspension for advanced Parkinson’s disease with motor fluctuations. The product entered the U.S. market in 2015 and occupies a high-value but narrow segment: patients requiring continuous levodopa delivery after oral regimens no longer provide adequate control. Its commercial profile is constrained by PEG-J tube placement, pump dependence, procedure-related costs, and competition from newer continuous-delivery therapies.

AbbVie does not separately report DUOPA revenue in its public financial statements. The company reports broader neuroscience and product-category results, preventing a reliable standalone revenue series. DUOPA remains commercially relevant because it addresses advanced disease, but its long-term growth ceiling is limited by the invasive delivery system and the launch of subcutaneous foslevodopa/foscarbidopa, marketed in the U.S. as VYALEV.

What is DUOPA and how does the product work?

DUOPA is a levodopa-carbidopa enteral suspension delivered directly into the jejunum through a PEG-J tube and a portable infusion pump. It is approved for the treatment of motor fluctuations in patients with advanced Parkinson’s disease who respond to levodopa treatment but have significant fluctuations despite optimized oral therapy (U.S. Food and Drug Administration [FDA], 2015).

DUOPA active ingredients and delivery system

Attribute	DUOPA detail
Active ingredients	Levodopa and carbidopa
Dosage form	Enteral suspension
Administration	Continuous jejunal infusion
Delivery device	Portable infusion pump
Access route	PEG-J tube
FDA indication	Motor fluctuations in advanced Parkinson’s disease
U.S. approval	January 2015
Sponsor	AbbVie Inc.
NDA	203312
Typical use	Daytime infusion, with oral supplementation when needed

The product concentration is approximately 20 mg/mL of levodopa and 5 mg/mL of carbidopa. A standard 100-mL cassette contains 2,000 mg of levodopa and 500 mg of carbidopa. The formulation is intended to reduce the peaks and troughs associated with intermittent oral dosing by maintaining more continuous levodopa exposure (FDA, 2015).

How large is the DUOPA market?

DUOPA addresses a small patient population relative to oral Parkinson’s medicines, but the target patients have high treatment intensity and high healthcare utilization. The commercial opportunity depends more on penetration among advanced Parkinson’s patients than on broad disease prevalence.

Parkinson’s disease affects more than 8.5 million people globally, according to the World Health Organization. Only a fraction develop the combination of severe motor fluctuations, levodopa responsiveness, and treatment burden required for enteral infusion therapy (World Health Organization, 2023).

Key demand drivers

The principal demand drivers are:

• Increased prevalence of Parkinson’s disease with population aging.
• Longer survival after diagnosis.
• Persistent “off” episodes despite oral levodopa.
• Clinical demand for continuous dopaminergic stimulation.
• Specialist-center familiarity with PEG-J procedures and pump management.
• Reimbursement for advanced therapies in Medicare and commercial plans.

Key market constraints

DUOPA adoption is restricted by:

• The need for endoscopic PEG-J placement.
• Tube dislodgement, occlusion, infection, and replacement.
• Pump training and daily cassette handling.
• Device-related inconvenience.
• Caregiver burden.
• Dependence on movement-disorder specialists and infusion infrastructure.
• Competition from deep brain stimulation, apomorphine, inhaled levodopa, and newer infusion systems.

The product therefore has a concentrated commercial footprint. Revenue depends on specialist prescribing and durable patient retention rather than rapid primary-care adoption.

What is the financial trajectory for DUOPA?

AbbVie does not publish a separate DUOPA revenue line in its annual reports. Its disclosed financial reporting groups products into broader therapeutic categories and reports selected products individually when material to consolidated results (AbbVie, 2024a, 2024b).

Public financial visibility

Financial question	Public answer
Standalone DUOPA revenue	Not separately disclosed by AbbVie
Standalone operating profit	Not disclosed
Patient count	Not disclosed in regular SEC filings
Product-level gross margin	Not disclosed
Revenue category	Included within AbbVie’s broader neuroscience reporting
Forecast reliability	Limited without company-reported product sales

DUOPA’s financial trajectory is best characterized as a niche, mature-product profile rather than a high-growth franchise. Its revenue likely benefited from the initial conversion of advanced Parkinson’s patients after the 2015 launch, followed by a more mature pattern shaped by new patient starts, discontinuations, tube complications, reimbursement, and competitive entry.

AbbVie’s acquisition of Allergan in 2020 did not materially change DUOPA’s underlying delivery model or indication. The transaction expanded AbbVie’s overall neuroscience and specialty-care portfolio but did not create a publicly reported DUOPA-specific growth program (AbbVie, 2020).

Commercial economics

DUOPA can generate attractive revenue per treated patient because it combines:

• Specialty pharmaceutical supply.
• A pump-based administration model.
• PEG-J procedure management.
• Ongoing clinical monitoring.
• Replacement and maintenance services.

The same complexity can reduce net commercial value. Treatment interruptions, tube complications, discontinuation after implantation, and reimbursement friction can lower realized revenue per patient. The product’s economics also depend on whether payers treat the drug, pump, procedure, and supplies under separate benefit categories.

When did DUOPA lose exclusivity?

DUOPA did not face the same exclusivity profile as a newly discovered small molecule because levodopa and carbidopa are long-established active ingredients. Its commercial protection depends primarily on the specific suspension formulation, delivery method, device configuration, manufacturing process, and regulatory exclusivity attached to the NDA.

FDA regulatory exclusivity

The FDA approved DUOPA in January 2015 under NDA 203312. A new chemical entity exclusivity period was not available because levodopa and carbidopa were previously approved active ingredients. The product’s commercial protection therefore depended more heavily on patents and the practical difficulty of replicating the complete PEG-J infusion system (FDA, 2015; FDA, 2024a).

The product’s exclusivity should be separated into four categories:

1. Active-ingredient exclusivity: limited because the ingredients are old.
2. Formulation patents: potentially relevant to the aqueous suspension and stability profile.
3. Method-of-use patents: potentially relevant to continuous jejunal delivery and treatment of motor fluctuations.
4. Device and manufacturing protection: potentially relevant to cassettes, pump operation, and production controls.

What patents protect DUOPA?

DUOPA’s protection is not equivalent to a single composition-of-matter patent covering a new active ingredient. The relevant estate is a combination of formulation, administration, manufacturing, and potentially device-related rights.

Patent categories relevant to DUOPA

Patent category	Commercial relevance
Suspension formulation	Protects concentration, stability, excipients, and physical properties
Enteral delivery method	Covers administration through jejunal access and continuous infusion
Treatment method	May cover reducing motor fluctuations or improving levodopa exposure
Cassette and pump system	Can create operational barriers even when drug patents expire
Manufacturing process	May complicate development of an equivalent suspension
Regulatory listing	Determines whether an ANDA applicant must certify against listed patents

The FDA Orange Book is the controlling public source for patents listed against NDA 203312. Patent status can change through expiration, disclaimer, litigation, delisting, terminal-disclaimer analysis, or court decisions. A definitive current patent-expiration assessment requires matching the latest Orange Book listing against the relevant U.S. patent records and litigation docket (FDA, 2024a; U.S. Patent and Trademark Office, 2024).

Is DUOPA vulnerable to generic competition?

Yes, but generic entry is operationally more difficult than for a conventional oral tablet. An ANDA applicant would need to address more than active ingredients and strength. Bioequivalence, formulation performance, administration compatibility, cassette handling, and labeling must align with the reference product.

Potential barriers include:

• Complex suspension characteristics.
• Stability during storage and use.
• Compatibility with the infusion pump and tubing.
• PEG-J administration requirements.
• Specialized pharmacokinetic testing.
• Limited commercial scale.
• Small prescriber base.
• Product liability and device-integration exposure.

These barriers can delay entry even if core patent protection is weak. They do not create permanent exclusivity. A successful applicant could compete through an ANDA, a 505(b)(2) application, or a combination product strategy, depending on the proposed product and required changes.

What is the Orange Book status of DUOPA?

DUOPA is listed by the FDA under NDA 203312. The Orange Book determines whether AbbVie has listed patents that an ANDA applicant must address through a Paragraph IV certification or other patent certification pathway (FDA, 2024a).

A current Orange Book review should assess:

• Active patent listings for NDA 203312.
• Patent-use codes.
• Listed expiration dates.
• Pediatric-exclusivity adjustments.
• Whether patents cover the formulation, method of use, or delivery system.
• Whether any listed patent has been challenged or delisted.

The public record does not support treating DUOPA as protected by a conventional long-dated molecule patent. The more important question is whether formulation and administration patents remain enforceable against a technically substitutable product.

Which companies are challenging or competing with DUOPA?

The competitive field includes both direct continuous-infusion products and alternative advanced Parkinson’s therapies.

VYALEV

VYALEV is the most important newer direct competitor. The FDA approved foslevodopa and foscarbidopa for adults with advanced Parkinson’s disease who experience motor fluctuations despite treatment with oral medicines (FDA, 2024b). The product uses continuous subcutaneous infusion, eliminating the need for PEG-J placement.

VYALEV’s advantages include:

• No surgical jejunal access.
• Subcutaneous rather than enteral administration.
• Potentially simpler initiation and maintenance.
• A delivery model more compatible with outpatient care.

Its risks include infusion-site reactions, pump dependence, potential device burden, and the need to establish broad reimbursement and specialist adoption.

INBRIJA

INBRIJA is inhaled levodopa for intermittent treatment of “off” episodes. It is not a direct replacement for continuous DUOPA therapy because it treats episodic symptoms rather than providing continuous levodopa delivery (FDA, 2018).

Apomorphine products

Subcutaneous apomorphine injection and infusion products compete for advanced Parkinson’s patients with motor fluctuations. They use a different pharmacologic mechanism and may be limited by nausea, hypotension, skin reactions, and titration complexity.

Deep brain stimulation

Deep brain stimulation competes for the same specialist population but is a surgical neuromodulation procedure rather than a levodopa-delivery product. Patient selection, age, cognition, disease phenotype, and surgical risk determine whether DBS is considered instead of DUOPA.

How does DUOPA compare with VYALEV?

Factor	DUOPA	VYALEV
Active therapy	Levodopa/carbidopa	Foslevodopa/foscarbidopa
Delivery route	PEG-J enteral infusion	Subcutaneous infusion
FDA approval	2015	2024
Surgical access	Required	Not required for drug delivery
Primary burden	Tube, pump, procedure	Pump and infusion-site management
Market position	Established niche	New entrant
Generic risk	Formulation and device complexity	Newer product, likely stronger early exclusivity
Main commercial risk	Patient attrition and substitution	Reimbursement and adoption

VYALEV is likely to place the greatest pressure on DUOPA’s new-patient starts. Existing DUOPA patients may remain on therapy because of clinical familiarity, established tube access, and physician experience. Conversion rates will depend on comparative symptom control, adverse events, payer policy, and the practical burden of replacing PEG-J therapy.

What patent litigation and Paragraph IV risks affect DUOPA?

No major public litigation event should be treated as proof of imminent generic entry without a current docket and Orange Book review. A Paragraph IV challenge would be commercially significant because it could trigger litigation, a 30-month stay under the Hatch-Waxman framework, and possible settlement negotiations.

Likely litigation issues

DUOPA litigation would likely focus on:

• Whether an abbreviated applicant infringes formulation claims.
• Whether the proposed product uses the same concentration or excipient system.
• Whether method-of-use claims are properly listed.
• Whether a carve-out label avoids infringement.
• Whether the reference product’s pump and cassette are part of the approved drug product.
• Whether patent claims are invalid for obviousness, anticipation, or inadequate written description.

A settlement could establish a licensed generic entry date, but no public settlement should be assumed without a filed agreement, court docket, or regulatory record.

What manufacturing and intellectual-property barriers protect DUOPA?

The strongest practical barriers are likely manufacturing and product-integration barriers rather than active-ingredient novelty.

A competing manufacturer must develop:

• A stable levodopa-carbidopa suspension.
• Consistent particle-size and suspension behavior.
• Compatible primary packaging.
• A reliable cassette-filling process.
• Cold-chain or storage controls as required by the approved product.
• Compatibility with the relevant pump and tubing.
• A validated quality system for a sterile or controlled specialty product.
• Clinical and bioequivalence evidence adequate for FDA review.

These requirements reduce the number of credible entrants. They also raise the cost of a generic launch in a market with a relatively small patient population.

What geographic markets does DUOPA cover?

DUOPA’s strongest commercial position is in the United States, where AbbVie obtained FDA approval and established the product’s specialty-care infrastructure. Availability and product naming differ by jurisdiction. Patent duration, reimbursement, PEG-J practice, and regulatory classification also vary across the United States, Europe, Japan, and other markets.

Geographic risk depends on:

• Local patent filings.
• National reimbursement systems.
• Availability of movement-disorder specialists.
• Adoption of DBS and other advanced therapies.
• Regulatory treatment of the pump and enteral system.
• Local manufacturing and distribution arrangements.

U.S. revenue remains the most relevant public-market issue because AbbVie’s SEC reporting and FDA listing provide the clearest commercial and regulatory record.

What is the outlook for DUOPA revenue?

DUOPA revenue is likely to remain stable to declining over the medium term unless AbbVie expands patient access, improves delivery convenience, or secures a differentiated reimbursement position. The product has durable demand among established patients but faces pressure in new starts from VYALEV and other advanced-therapy options.

Base-case commercial outlook

• Existing-patient retention supports recurring revenue.
• New-patient growth is limited by PEG-J invasiveness.
• VYALEV increases competitive pressure after its 2024 U.S. approval.
• Generic risk is delayed by formulation and delivery complexity.
• AbbVie’s lack of standalone disclosure indicates that DUOPA is not a separately material reporting line.
• The product remains strategically useful but is unlikely to become a major growth driver for AbbVie.

Key Takeaways

• DUOPA is a mature, specialty Parkinson’s product based on continuous jejunal levodopa/carbidopa infusion.
• AbbVie does not disclose standalone DUOPA revenue, preventing a reliable product-level financial series.
• The product’s commercial value comes from high treatment intensity and recurring specialty use, not a broad patient base.
• PEG-J placement, pump dependence, tube complications, and caregiver burden limit adoption.
• VYALEV is the most important new direct competitor because it provides continuous levodopa therapy through subcutaneous infusion.
• DUOPA’s protection depends on formulation, method-of-use, manufacturing, and delivery-system rights rather than a new-molecule patent.
• Generic entry is technically possible but more difficult than for oral carbidopa/levodopa.
• The medium-term outlook is mature to declining, with the greatest risk concentrated in new-patient starts.

FAQs

Is DUOPA still available in the United States?

Yes. DUOPA remains an FDA-approved product marketed by AbbVie for motor fluctuations in advanced Parkinson’s disease.

Is DUOPA a biologic drug?

No. DUOPA is a small-molecule drug product containing levodopa and carbidopa in an enteral suspension.

Can DUOPA be replaced by oral carbidopa/levodopa?

Oral therapy may be used for some patients, but DUOPA is intended for advanced patients whose motor fluctuations are not adequately controlled with optimized oral treatment.

Does DUOPA require surgery?

DUOPA requires PEG-J placement to deliver the suspension into the jejunum. The procedure creates a meaningful adoption and maintenance barrier.

Will VYALEV replace DUOPA?

VYALEV is likely to compete most directly for new advanced-Parkinson’s patients who need continuous levodopa delivery but want to avoid PEG-J placement. It is unlikely to displace all established DUOPA patients because clinical response, tube status, payer policy, and physician preference vary.

References

1. AbbVie Inc. (2020). Annual report 2019. https://www.abbvie.com
2. AbbVie Inc. (2024a). Annual report 2023. https://www.abbvie.com
3. AbbVie Inc. (2024b). Annual report 2024. https://www.abbvie.com
4. U.S. Food and Drug Administration. (2015). DUOPA prescribing information. https://www.accessdata.fda.gov
5. U.S. Food and Drug Administration. (2018). INBRIJA prescribing information. https://www.accessdata.fda.gov
6. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
7. U.S. Food and Drug Administration. (2024b). FDA approves new treatment for adults with Parkinson’s disease. https://www.fda.gov
8. U.S. Patent and Trademark Office. (2024). Patent Center. https://patentcenter.uspto.gov
9. World Health Organization. (2023). Parkinson disease. https://www.who.int/news-room/fact-sheets/detail/parkinson-disease

DrugChatter Q&A for DUOPA

Duopa expiry date?